Skip to main content

Australian Pharmacies Can Now Sell CBD Without A Prescription

cbd oil cbd oil cbd oil cbd oil cbd oil cbd oil cbd oil cbd oil cbd oil cbd oil cbd oil cbd oil

Cannabidiol (CBD) is arguably the most popular cannabinoid on earth right now, even ahead of  THC. THC is obviously still very popular, however, CBD is searched for more often on Google than its cannabinoid counterpart.

CBD is being infused into just about anything and everything, for better or worse. Some CBD products make sense, such as capsules and topicals. However, some products out there such as ‘CBD firewood’ is a headscratcher for sure.

Regardless of the merits of some CBD products, the fact of the matter is that CBD is extremely popular, with more and more patients and consumers looking to CBD for wellness benefits.

In many countries, such as in the United States, CBD products can be purchased virtually anywhere. CBD-infused products are very commonly found around the world.

With that in mind, it is odd that CBD required a prescription in Australia, where reefer madness was preventing the non-intoxicating cannabinoid from being freely sold. Fortunately, that is changing. Per News.Com.Au:

Low-dose cannabidiol (CBD) can be sold in pharmacies around Australia from today, for the first time without prescription.

The chemical compound – extracted from cannabis – is used to treat a number of health issues, including pain, insomnia and anxiety, and can now be bought over-the-counter after the Therapeutic Goods Administration (TGA) approved its sale last month.

While the product will only be available to adults in doses of no more than 150 milligrams per day, patients will no longer require a referral or special approval for its legal use.

Ideally, there would be no limit on the amount of CBD that people can purchase without a prescription, but for now, this move by Australia is a great step in the right direction.

CBD does not possess the same euphoric-inducing qualities that THC does, and by virtually every measure it’s benign from a risk standpoint, so it doesn’t make sense to limit non-prescription sales to low-dose options only.

Australia